Plasmapheresis for Nephrogenic Fibrosing Dermopathy (NFD)/Nephrogenic Systemic Fibrosis (NSF)

Phase 4

Terminated

• Conditions: Nephrogenic Systemic Fibrosis; Nephrogenic Fibrosing Dermopathy
• Interventions: Procedure: Plasmapheresis

• Registration Number: NCT01078987
• Lead Sponsor: Loma Linda University

Brief Summary

The purpose of this study is to evaluate the pathophysiology of nephrogenic fibrosing dermopathy (NFD)/nephrogenic systemic fibrosis (NSF).

Detailed Description

Not available

Study Timeline

• Study Start: 2002-02
• Study First Submitted: 2010-02-05
• Study First Submitted QC: 2010-03-01
• Study First Posted: 2010-03-02
• Primary Completion: 2012-03
• Study Completion: 2012-03
• Status Verified: 2014-11
• Last Update Submitted: 2014-11-19
• Last Update Posted: 2014-11-21

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 12

Inclusion Criteria

• diagnosed with NFD/NSF following a kidney transplant
• diagnosed with NFD/NSF following a liver transplant
• NFD/NSF and who have not had a kidney or liver transplant
• diagnosed with NFD/NSF and who have not had a kidney or liver transplant

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Group 1	Plasmapheresis	One to three 5-day course of plasma exchange (plasmapheresis)
Group 2	Plasmapheresis	One to three 5-day course of plasma exchange (plasmapheresis)
Group 4	Plasmapheresis	One to three 5-day course of plasma exchange (plasmapheresis)

Primary Outcome Measures

Name	Time	Method
Improve elasticity of skin, including increased range of motion of compromised joints due to leathery skin	Assessed two weeks after each monthly course of plasmapheresis

Trial Locations

Locations (1)

Loma Linda University Medical Center; 🇺🇸 Loma Linda, California, United States